This review explores the role of dysregulated lipid metabolism in cancer and its potential as a therapeutic target. Lipid metabolism is essential for energy production, membrane synthesis, and cell signaling, and its dysregulation contributes to cancer progression. Key pathways involved include fatty acid synthesis, oxidation, and cholesterol metabolism, which are critical for cancer cell survival, proliferation, and metastasis. Oncogenic signaling pathways such as PI3K/AKT/mTOR, JAK/STAT, Hippo, and NF-κB intersect with lipid metabolism to drive tumour progression. Altered lipid signaling in the tumour microenvironment also contributes to immune dysfunction, exacerbating oncogenesis. The review highlights the importance of lipid metabolism in tumour initiation, invasion, metastasis, and cancer stem cell maintenance. It discusses the role of epigenetic modulators in these processes and reviews metabolic drugs in cancer therapeutics. The review also examines the therapeutic opportunities of targeting lipid metabolism in cancer, including the use of pharmacological inhibitors to disrupt fatty acid uptake, synthesis, and oxidation. Key targets include CD36, FABP4, FATP1, ACC, FASN, SCD, and CPT1A, with various inhibitors and antibodies showing promise in preclinical studies. Additionally, the review explores the link between epigenetic modifications and lipid metabolism, highlighting the role of histone acetylation, SREBPs, and other regulatory mechanisms in cancer progression. Overall, the review underscores the potential of targeting lipid metabolism as a novel therapeutic strategy in cancer treatment.This review explores the role of dysregulated lipid metabolism in cancer and its potential as a therapeutic target. Lipid metabolism is essential for energy production, membrane synthesis, and cell signaling, and its dysregulation contributes to cancer progression. Key pathways involved include fatty acid synthesis, oxidation, and cholesterol metabolism, which are critical for cancer cell survival, proliferation, and metastasis. Oncogenic signaling pathways such as PI3K/AKT/mTOR, JAK/STAT, Hippo, and NF-κB intersect with lipid metabolism to drive tumour progression. Altered lipid signaling in the tumour microenvironment also contributes to immune dysfunction, exacerbating oncogenesis. The review highlights the importance of lipid metabolism in tumour initiation, invasion, metastasis, and cancer stem cell maintenance. It discusses the role of epigenetic modulators in these processes and reviews metabolic drugs in cancer therapeutics. The review also examines the therapeutic opportunities of targeting lipid metabolism in cancer, including the use of pharmacological inhibitors to disrupt fatty acid uptake, synthesis, and oxidation. Key targets include CD36, FABP4, FATP1, ACC, FASN, SCD, and CPT1A, with various inhibitors and antibodies showing promise in preclinical studies. Additionally, the review explores the link between epigenetic modifications and lipid metabolism, highlighting the role of histone acetylation, SREBPs, and other regulatory mechanisms in cancer progression. Overall, the review underscores the potential of targeting lipid metabolism as a novel therapeutic strategy in cancer treatment.